BIBLIOS

  Ciências References Management System

Visitor Mode (Login)
Need help?


Back

Publication details

Document type
Journal articles

Document subtype
Full paper

Title
Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A>G

Participants in the publication
Iris A.L. Silva (Author)
BIOISI - Instituto de Biossistemas e Ciências Integrativas
Tereza Doušová (Author)
Sofia Ramalho (Author)
BioISI - Biosystems & Integrative Sciences Institute
Raquel Centeio (Author)
BioISI - Biosystems & Integrative Sciences Institute
Luka A. Clarke (Author)
BIOISI - Instituto de Biossistemas e Ciências Integrativas
Violeta Railean (Author)
Hugo M. Botelho (Author)
BIOISI - Instituto de Biossistemas e Ciências Integrativas
Andrea Holubová (Author)
Iveta Valášková (Author)
Jiunn-Tyng Yeh (Author)
Tzyh-Chang Hwang (Author)
Carlos M. Farinha (Author)
Dep. Química e Bioquímica
BIOISI - Instituto de Biossistemas e Ciências Integrativas
Karl Kunzelmann (Author)
UNIVERSITÄT REGENSBURG
Margarida D. Amaral (Author)
Dep. Química e Bioquímica
BIOISI - Instituto de Biossistemas e Ciências Integrativas

Scope
International

Refereeing
Yes

Summary
Background: For most of the >2000 CFTR gene variants reported, neither the associated disease liability nor the underlying basic defect are known, and yet these are essential for disease prognosis and CFTR-based therapeutics. Here we aimed to characterize two ultra-rare mutations - 1717-2A > G (c.1585-2A > G) and S955P (p.Ser955Pro) - as case studies for personalized medicine.\n\nMethods: Patient-derived rectal biopsies and intestinal organoids from two individuals with each of these mutations and F508del (p.Phe508del) in the other allele were used to assess CFTR function, response to modulators and RNA splicing pattern. In parallel, we used cellular models to further characterize S955P independently of F508del and to assess its response to CFTR modulators.\n\nResults: Results in both rectal biopsies and intestinal organoids from both patients evidence residual CFTR function. Further characterization shows that 1717-2A > G leads to alternative splicing generating <1% normal CFTR mRNA and that S955P affects CFTR gating. Finally, studies in organoids predict that both patients are responders to VX-770 alone and even more to VX-770 combined with VX-809 or VX-661, although to different levels.\n\nConclusion: This study demonstrates the high potential of personalized medicine through theranostics to extend the label of approved drugs to patients with rare mutations.

Date of Submisson/Request
2020-01-14
Date of Acceptance
2020-07-22
Date of Publication
2020-11

Where published
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Publication Identifiers
ISSN - 0925-4439

Publisher
Elsevier BV

Volume
1866
Number
11

Starting page
165905

Document Identifiers
DOI - https://doi.org/10.1016/j.bbadis.2020.165905
URL - http://dx.doi.org/10.1016/j.bbadis.2020.165905

Rankings
SCIMAGO Q1 (2016) - 2.593 - Molecular Biology
SCIMAGO Q1 (2017) - 2.496 - Molecular Biology
SCIMAGO Q1 (2018) - 1.843 - Molecular Medicine
SCOPUS Q1 (2011) - 2.488 - Molecular Medicine
SCOPUS Q1 (2012) - 2.473 - Molecular Medicine
SCOPUS Q1 (2013) - 2.351 - Molecular Medicine
SCOPUS Q1 (2014) - 2.324 - Molecular Medicine
SCOPUS Q1 (2015) - 2.8 - Molecular Medicine
SCOPUS Q1 (2016) - 2.593 - Molecular Medicine
SCOPUS Q1 (2017) - 2.496 - Molecular Medicine
Web Of Science Q1 (2017) - 5.108 - BIOCHEMISTRY & MOLECULAR BIOLOGY - SCIE
Web Of Science Q1 (2018) - 4.328 - BIOCHEMISTRY & MOLECULAR BIOLOGY - SCIE
SCIMAGO Q1 (2019) - 1.649 - Molecular Medicine
SCOPUS Q1 (2019) - 7.7 - Molecular Medicine
Web Of Science 4.352 (2019) - Q1 - BIOPHYSICS - SCIE

Keywords
CFTR modulators Intestinal organoids Precision medicine Rare mutations Theranostics


Export

APA
Iris A.L. Silva, Tereza Doušová, Sofia Ramalho, Raquel Centeio, Luka A. Clarke, Violeta Railean, Hugo M. Botelho, Andrea Holubová, Iveta Valášková, Jiunn-Tyng Yeh, Tzyh-Chang Hwang, Carlos M. Farinha, Karl Kunzelmann, Margarida D. Amaral, (2020). Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A>G. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1866, ISSN 0925-4439. eISSN . http://dx.doi.org/10.1016/j.bbadis.2020.165905

IEEE
Iris A.L. Silva, Tereza Doušová, Sofia Ramalho, Raquel Centeio, Luka A. Clarke, Violeta Railean, Hugo M. Botelho, Andrea Holubová, Iveta Valášková, Jiunn-Tyng Yeh, Tzyh-Chang Hwang, Carlos M. Farinha, Karl Kunzelmann, Margarida D. Amaral, "Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A>G" in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1866, 2020. 10.1016/j.bbadis.2020.165905

BIBTEX
@article{48137, author = {Iris A.L. Silva and Tereza Doušová and Sofia Ramalho and Raquel Centeio and Luka A. Clarke and Violeta Railean and Hugo M. Botelho and Andrea Holubová and Iveta Valášková and Jiunn-Tyng Yeh and Tzyh-Chang Hwang and Carlos M. Farinha and Karl Kunzelmann and Margarida D. Amaral}, title = {Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A>G}, journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease}, year = 2020, volume = 1866 }